Description

Eli Lilly’s Obesity Franchise Is Expanding Fast—What’s The Real Upside Beyond Zepbound?

Eli Lilly and Company began 2026 with substantial growth across multiple fronts. The company reported a 56% increase in revenue for Q1 compared to the same period in 2025, driven largely by strong sales of key products such as Zepbound, Mounjaro, Ebglyss, Inluriyo, Jaypirca, Kisunla, Omvoh, and Foundayo, a newly approved oral GLP-1 therapy for obesity. Foundayo represents a novel approach as the first incretin medicine launched specifically for obesity, offering an oral alternative without food or water restrictions. Although its commercial rollout is early, the company highlighted positive initial feedback from payers, physicians, and patients, with extensive efforts underway to build broad access in commercial insurance, Medicare via the Bridge program, and upcoming Medicaid access. Geographically, U.S. revenue increased by 43%, primarily from volume growth despite anticipated price declines.